GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
N

Neurosense Therapeutics NRSN · USD

Health Care · US listing · 🇺🇸 United States

Compare

1.86

+10.71%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Neurosense Therapeutics

Its shares trade under the ticker NRSN. It has been listed since 9 December 2021.

Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company. The firm is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The firm's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
9 Dec 2021
Employees
14
Head office
11 HAMENOFIM ST., HERZLIYA, L3, 4672562
Incorporated in
L3
Classification
Pharmaceutical Preparations
Filer status
Non-accelerated filer<br>Emerging growth company

Leadership

Pay as last reported

  • Mr. Mark LeuchtenbergerIndependent Non-Executive Chairman of the Board
  • Mr. Alon Ben-NoonChief Executive Officer, Director, since 2017
  • Mr. Or EisenbergChief Financial Officer
  • Dr. Ferenc TracikChief Medical Officer
  • Mr. Cary ClaiborneNon-Executive Independent Director
  • Ms. Caren DeardorfNon-Executive Independent Director
  • Dr. Revital Mandil-LevinNon-Executive Independent Director
  • Ms. Christine PellizzariNon-Executive Independent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Neurosense Therapeutics Ltd. focuses on ALS and neurodegenerative diseases with PrimeC oral treatment.
  • The company has 14 employees dedicated to clinical-stage biotechnology research and development.
  • PrimeC is an oral fixed-dose combination for ALS patients in clinical development.

Weaknesses

  • Neurosense Therapeutics Ltd. has only 14 employees for a clinical-stage biotechnology company.
  • The company's lead product PrimeC is still in clinical development for ALS treatment.
  • Neurosense Therapeutics Ltd. operates in Herzliya, Israel, with limited global presence.

Opportunities

  • Neurosense Therapeutics Ltd. can expand PrimeC to Alzheimer's and Parkinson's disease research.
  • The biotechnology sector in Israel offers growth potential for Neurosense Therapeutics Ltd.
  • The global market for ALS treatments presents significant opportunities for Neurosense Therapeutics Ltd.

Threats

  • Neurosense Therapeutics Ltd. faces competition from other biotechnology companies in ALS treatment.
  • The clinical development of PrimeC may encounter regulatory hurdles in the United States.
  • Neurosense Therapeutics Ltd. must navigate the high costs of biotechnology research and development.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.